心血管疾病是世界上最大的殺手之一，根據世界衛生組織的數據，每年會有1750萬人發病，並使數百萬人喪生。目前，沒有藥物可以恢復心臟病發作後的心肌功能。而在最近的研究找到了可在心肌受損後再回復心肌功能的候選藥物，MSI-1436。目前已在斑馬魚與小鼠進行實驗，未來也會在豬隻上進行心肌細胞再生研究，此研究也發表在《npj 再生醫學》期刊（npj Regenerative Medicine）中。
Cardiovascular disease is the world's
leading killer, taking the lives of 17.5 million people annually, according to
the World Health Organization, and disabling millions more. Currently, no drug
exists to restore heart muscle function after a heart attack.
"The potential impact of MSI-1436 is
enormous," MDI Biological Laboratory scientist Viravuth P. Yin, Ph.D., one
of the paper's authors, said. "If it shows similar results in humans, it
will be a game-changer for patients who suffer a heart attack and/or are living
with heart disease."
The institution is seeking to move the drug
into human clinical trials through a spinoff company, Novo Biosciences. The
next step is to test the drug in pigs, the animal whose heart most closely
resembles that of humans.
The drug has two advantages that are
expected to smooth the path to the clinic. First, MSI-1436 stimulates tissue
regeneration in zebrafish and mice, which are separated by approximately 450
million years of evolution. This increases the likelihood it will work in
humans too. Second, it has already been shown to be well tolerated by patients
in Phase 1 and 1b clinical trials for an unrelated indication. The maximum
well-tolerated human dose is 5 to 50 times higher than the dose shown to be
effective in stimulating heart repair in zebrafish and mice.
"The previous clinical trials of
MSI-1436 make a big difference in bringing this drug to market," said
Kevin Strange, Ph.D., president of the MDI Biological Laboratory and one of the
paper's authors. "The path from laboratory bench to patient bedside can be
long and difficult. But the fact that MSI-1436 has been shown to be safe for
use in humans shaves years off the drug development process."
Strange is also the CEO and co-founder of
Novo Biosciences and the co-inventor of MSI-1436, along with Yin and
collaborator Michael A. Zasloff, M.D., Ph.D. Yin is the co-founder and chief
scientific officer of Novo Biosciences. The scientists have been issued a
patent on the use MSI-1436 for the treatment of heart disease.
The original research on MSI-1436 was
conducted by Yin in zebrafish, an organism that can regenerate the form and
function of almost any body part. He found that the administration of MSI-1436
increased appendage regeneration by 200 to 300 percent. Follow-up research
showed that MSI-1436 also stimulated zebrafish heart regeneration to the same
"That was definitely a 'Eureka!'
moment," Yin said of the day in the laboratory when the appendage study
was conducted. He was so astonished by the results that he repeated the study
several times and under different conditions.
Yin followed the studies in zebrafish with
studies in adult mice, which, like humans, have a limited capacity for
regeneration. The goal was to see if MSI-1436 could stimulate regeneration in
higher organisms. Though mammals such as mice and humans share the genetic pathways
for regeneration with zebrafish, they have been largely deactivated for reasons
that are still unclear.
The results in mice, which are detailed in
the paper, show that the administration of MSI-1436 24 hours after an
artificially induced heart attack increased survival; improved heart function
two- to three-fold; reduced the size of the infarct or scar tissue by 53
percent; reduced ventricular wall thinning; and stimulated heart muscle cell
proliferation in the infarct border zone by six-fold.
When a patient suffers a heart attack, part
of the heart muscle dies and the associated scarring interferes with the
heart's ability to effectively pump blood. The authors believe MSI-1436 to be
the first drug candidate that has been shown to reduce scarring and induce
heart regeneration in an adult mammal.
Strange and Yin view their MSI-1436 results
as a validation of the MDI Biological Laboratory's and Novo Biosciences' unique
approach to regenerative medicine. Regenerative medicine has focused on complex
stem cell, gene and tissue-engineering approaches for the last 15 years or
more, but thus far these approaches have failed to deliver on their promise,
despite the investment of hundreds of millions of dollars.
By contrast, MDI Biological Laboratory and
Novo Biosciences scientists are focused on decoding the instruction manual for
repair and regeneration that has been conserved by evolution in human DNA for
hundreds of millions of years. This approach has been very effective: in only a
few years and at modest cost, they have identified three potential regenerative
"If we can decode the instruction
manual for regeneration in highly regenerative species," Yin said,
"we can use drug therapies to reignite our own dormant regenerative
capacity. Our research in these highly regenerative species is showing that
regenerating damaged or lost tissues and organs could be as simple as taking a
MSI-1436 also has potential applications
for the regeneration of skeletal muscle tissue in Duchenne muscular dystrophy,
which is characterized by progressive muscle degeneration and untimely death
due to heart and/or respiratory failure. Other potential applications include
stimulation of wound healing and regeneration of multiple other tissues,
including nervous tissue.
Desert Island Biological Laboratory. " Scientists publish groundbreaking study on new heart drug.
" ScienceDaily, 16 March, 2017.
參考文獻：Ashley M et al., The protein tyrosine
phosphatase 1B inhibitor MSI-1436 stimulates regeneration of heart and multiple
other tissues. npj Regenerative Medicine,
2017. DOI: 10.1038/s41536-017-0008-1